Source: American heart journal. Unidade: FM
Subjects: ANTICORPOS MONOCLONAIS, INFECÇÕES POR HIV, HIPERCOLESTEROLEMIA, DISLIPIDEMIAS, RESULTADO DE TRATAMENTO, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, ESTATINAS, ENZIMAS PROTEOLÍTICAS, ESTUDOS MULTICÊNTRICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOCCARA, Franck et al. Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics. American heart journal, v. 220, p. 203-212, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.ahj.2019.11.004. Acesso em: 03 out. 2024.APA
Boccara, F., Kumar, P., Caramelli, B., Calmy, A., Lopez, J. A. G., Bray, S., et al. (2020). Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics. American heart journal, 220, 203-212. doi:10.1016/j.ahj.2019.11.004NLM
Boccara F, Kumar P, Caramelli B, Calmy A, Lopez JAG, Bray S, Cyrille M, Rosenson RS. Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics [Internet]. American heart journal. 2020 ; 220 203-212.[citado 2024 out. 03 ] Available from: https://doi.org/10.1016/j.ahj.2019.11.004Vancouver
Boccara F, Kumar P, Caramelli B, Calmy A, Lopez JAG, Bray S, Cyrille M, Rosenson RS. Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics [Internet]. American heart journal. 2020 ; 220 203-212.[citado 2024 out. 03 ] Available from: https://doi.org/10.1016/j.ahj.2019.11.004